Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-15

Clinical Trial Update: Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

View source ↗

Summary

A completed clinical trial comparing Spiolto Respimat (tiotropium/olodaterol) to triple therapy for COPD, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spiolto Respimat (tiotropium/olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED | Results posted: 2024-03-15